×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: aveed | low t | testosterone

New 'Low-T' Treatment Approved by FDA

Thursday, 06 March 2014 08:26 AM

Endo Health Solutions Inc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone drug, Aveed, to treat male hypogonadism.

The health regulator rejected the drug last May, saying that Endo needed a better plan to manage the risks associated with the drug.

Aveed, which contains testosterone and castor oil, is expected to be launched in early March, Endo said on Thursday.

Male hypogonadism is a condition characterized by low production of the hormone testosterone, often leading to a loss of libido, depression and fatigue.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
Endo Health Solutions Inc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone drug, Aveed, to treat male hypogonadism. The health regulator rejected the drug last May, saying that Endo needed a better plan to manage the risks associated with...
aveed,low t,testosterone
86
2014-26-06
Thursday, 06 March 2014 08:26 AM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved